Routine application of a novel MLPA-based first-line screening test uncovers clinically relevant copy number aberrations in haematological malignancies undetectable by conventional cytogenetics

References

• Haferlach T, Kern W, Schnittger S, Schoch C. Modern diagnostics in acute leukemias. Crit Rev Oncol Hematol. 2005;56:223–34.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukaemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999;77:266–81.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.
   PubMed Web of Science ®Google Scholar
• Savola S, Nardi F, Scotlandi K, Picci P, Knuutila S. Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenet Genome Res. 2007;119:21–6.
   PubMed Web of Science ®Google Scholar
• Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukaemia: a comprehensive review. Blood Rev. 2009;23:25–47.
   PubMed Web of Science ®Google Scholar
• Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA. 2004;101:1039–44.
   PubMed Web of Science ®Google Scholar
• Patel A, Kang SH, Lennon PA, Li YF, Rao PN, Abruzzo L, et al. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am J Hematol. 2008;83:540–6.
   PubMed Web of Science ®Google Scholar
• Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagnost. 2008;10:442–51.
   PubMed Web of Science ®Google Scholar
• Chapiro E, Leporrier N, Radford-Weiss I, Bastard C, Mossafa H, Leroux D, et al. Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leukemia Res. 2010;34:63–8.
   PubMed Web of Science ®Google Scholar
• Shao L, Kang SH, Li J, Hixson P, Taylor J, Yatsenko SA, et al. Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics. J Mol Diagnost. 2010;12:670–8.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Mian M, Kwee I, Rossi D, Deambrogi C, Mensah AA, et al. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Brit J Haematol. 2011;154:590–9.
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica. 2011;96:1161–9.
   PubMed Web of Science ®Google Scholar
• Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.
   PubMed Web of Science ®Google Scholar
• Coll-Mulet L, Santidrián AF, Cosialls AM, Iglesias-Serret D, de Frias M, Grau J, et al. Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia. Brit J Haematol. 2008;142:793–801.
   PubMed Web of Science ®Google Scholar
• Stevens-Kroef M, Simons A, Gorissen H, Feuth T, Weghuis DO, Buijs A, et al. Identification of chromosomal abnormalities relevant to prognosis in chronic lymphocytic leukemia using multiplex ligation-dependent probe amplification. Cancer Genet Cytogenet. 2009;195:97–104.
   PubMed Web of Science ®Google Scholar
• Al Zaabi EA, Fernandez LA, Sadek IA, Riddell DC, Greer WL. Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience. J Mol Diagnost. 2010;12:197–203.
   PubMed Web of Science ®Google Scholar
• Abdool A, Donahue AC, Wohlgemuth JG, Yeh CH. Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation- dependent probe amplification in chronic leukemia. PLoS ONE 2010;5:e15407.
   PubMed Web of Science ®Google Scholar
• Alpár D, de Jong D, Savola S, Yigittop H, Kajtár B, Kereskai L, et al. MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia. Cancer Genet. 2012;205:465–9.
   PubMed Web of Science ®Google Scholar
• Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosome Cancer. 2010;49:1104–13.
   PubMed Web of Science ®Google Scholar
• Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2011;117:6848–55.
   PubMed Web of Science ®Google Scholar
• Gardiner RB, Morash BA, Riddell C, Wang H, Fernandez CV, Yhap M, et al. Using MS-MLPA as an efficient screening tool for detecting 9p21 abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58:852–9.
   PubMed Web of Science ®Google Scholar
• Donahue AC, Abdool AK, Gaur R, Wohlgemuth JG, Yeh CH. Multiplex ligation-dependent probe amplification for detection of chromosomal abnormalities in myelodysplastic syndrome and acute myeloid leukemia. Leukemia Res. 2011;35:1477–83.
   PubMed Web of Science ®Google Scholar
• Coll-Mulet L, Gil J. Genetic alterations in chronic lymphocytic leukaemia. Clin Translational Oncol. 2009;11:194–8.
   PubMed Web of Science ®Google Scholar
• Fabris S, Scarciolla O, Morabito F, Cifarelli RA, Dininno C, Cutrona G, et al. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. Genes Chromosome Cancer. 2011;50:726–34.
   PubMed Web of Science ®Google Scholar
• Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16:49–58.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758–64.
   PubMed Web of Science ®Google Scholar
• Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. Lancet Oncol. 2009;10:125–34.
   PubMed Web of Science ®Google Scholar
• Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116:4874–84.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–4.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–80.
   PubMed Web of Science ®Google Scholar
• Georgopoulos K, Winandy S, Avitahl N. The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol. 1997;15:155–76.
   PubMed Web of Science ®Google Scholar
• Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113:100–7.
   PubMed Web of Science ®Google Scholar
• Heyman M, Rasool O, Borgonovo Brandter L, Liu Y, Grandér D, Söderhäll S, et al. Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol. 1996;14:1512–20.
   PubMed Web of Science ®Google Scholar
• Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 1997;89:4161–6.
   PubMed Web of Science ®Google Scholar
• Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999;94:1537–44.
   PubMed Web of Science ®Google Scholar
• Carter TL, Reaman GH, Kees UR. INK4A/ARF deletions are acquired at relapse in childhood acute lymphoblastic leukaemia: a paired study on 25 patients using real-time polymerase chain reaction. Br J Haematol. 2001;113:323–8.
   PubMed Web of Science ®Google Scholar
• Calero Moreno TM, Gustafsson G, Garwicz S, Grander D, Jonmundsson GK, Frost BM, et al. Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92. Leukemia. 2002;16:2037–45.
   PubMed Web of Science ®Google Scholar
• Dalle JH, Fournier M, Nelken B, Mazingue F, Laï JL, Bauters F, et al. p16(INK4a) immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood. 2002;99:2620–3.
   PubMed Web of Science ®Google Scholar
• van Zutven LJ, van Drunen E, de Bont JM, Wattel MM, Den Boer ML, Pieters R, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia. 2005;19:1281–4.
   PubMed Web of Science ®Google Scholar
• Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica. 2006;91:881–5.
   PubMed Web of Science ®Google Scholar
• Usvasalo A, Savola S, Räty R, Vettenranta K, Harila-Saari A, Koistinen P, et al. CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res. 2008;32:1228–35.
   PubMed Web of Science ®Google Scholar
• Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, et al. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum. Genet. 2009;126:511–20.
   PubMed Web of Science ®Google Scholar
• Kuchinskaya E, Heyman M, Nordgren A, Söderhäll S, Forestier E, Wehner P, et al. Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol. Br J Haematol. 2011;152:615–22.
   PubMed Web of Science ®Google Scholar
• Sarhadi VK, Lahti L, Scheinin I, Tyybäkinoja A, Savola S, Usvasalo A, et al. Targeted resequencing of 9p in acute lymphoblastic leukemia yields concordant results with array CGH and reveals novel genomic alterations. Genomics. 2013;102(3):182–8.
   Web of Science ®Google Scholar
• Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, et al. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood. 2010;115:3089–97.
   PubMed Web of Science ®Google Scholar
• Familiades J, Bousquet M, Lafage-Pochitaloff M, Bene MC, Beldjord K, De Vos J, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia. 2009;23:1989–98.
   PubMed Web of Science ®Google Scholar
• Ko DH, Jeon Y, Kang HJ, Park KD, Shin HY, Kim HK, et al. Native ETV6 deletions accompanied by ETV6-RUNX1 rearrangements are associated with a favourable prognosis in childhood acute lymphoblastic leukaemia: a candidate for prognostic marker. Brit J Haematol. 2011;155:530–3.
   PubMed Web of Science ®Google Scholar
• Akagi T, Ogawa S, Dugas M, Kawamata N, Yamamoto G, Nannya Y, et al. Frequent genomic abnormalities in acute myeloid leukemia/ myelodysplastic syndrome with normal karyotype. Haematologica. 2009;94:213–23.
   PubMed Web of Science ®Google Scholar
• Busson-Le Coniat M, Nguyen Khac F, Daniel MT, Bernard OA, Berger R. Chromosome 21 abnormalities with AML1 amplification in acute lymphoblastic leukemia. Genes Chromosomes Cancer 2001;32:244–9.
   PubMed Web of Science ®Google Scholar
• Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR, et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 2003;17:2249–50.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11:429–38.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 2005;434:1144–8.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Arai S, Ichikawa M, Nakagawa M, Goyama S, Kumano K, et al. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. Blood. 2011;118:2541–50.
   PubMed Web of Science ®Google Scholar
• De Braekeleer E, Douet-Guilbert N, Basinko A, Le Bris MJ, Morel F, Berthou C, et al. Distinct clonal anomalies involving RUNX1 in acute myeloid leukemia at diagnosis and after bone marrow transplantation. Ann Hematol. 2010;89:1277–81.
   PubMed Web of Science ®Google Scholar
• Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39:593–5.
   PubMed Web of Science ®Google Scholar
• Schultz RA, Delioukina M, Gaal K, Bedell V, Smith DD, Forman SJ, et al. Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis. Mol Cytogenet. 2011;4:4–18.
   PubMed Web of Science ®Google Scholar
• Gruver AM, Rogers HJ, Cook JR, Ballif BC, Schultz RA, Batanian JR, et al. Modified array-based comparative genomic hybridization detects cryptic and variant PML-RARA rearrangements in acute promyelocytic leukemia lacking classic translocations. Diagn Mol Pathol. 2013;22:10–21.
   PubMed Web of Science ®Google Scholar
• Liu F, Yoshida N, Suguro M, Kato H, Karube K, Arita K, et al. Clonal heterogeneity of mantle cell lymphoma revealed by array comparative genomic hybridization. Eur J Haematol. 2013;90:51–8.
   PubMed Web of Science ®Google Scholar